Biological Activity
SNDX-5613 is a potent and specific Menin-MLL inhibitor with a binding Ki of 0.149 nM and a cell based IC50 of 10-20 nM. SNDX-5613 can be used for the research of MLL-rearranged (MLL-r) acute leukemias, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML)[1].
In Vitro
No in vitro data are provided in the current product source. Contact us for further information.
In Vivo
SNDX-5613 shows in vivo plasma IC50 of 53 nM. SNDX-5613 treatment provides significant survival benefit and leukemic control in aggressive MOLM-13 disseminated xenografts[1].
Target
Menin-MLL[1]
References & source
[1]. A drug, SNDX-5613, to treat acute leukemia with a KMT2A translocation or an NPM1 mutation that has come back (relapsed) or has not gotten better with treatment (refractory).
Published experimental findings depend on the model and assay conditions. They do not guarantee equivalent performance in every application. For laboratory research use only.
